Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:ARVNNASDAQ:KYMRNASDAQ:NAMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$24.31-3.4%$21.10$16.50▼$26.50$2.12BN/A69,148 shs9,839 shsARVNArvinas$6.61-2.9%$8.65$5.94▼$37.38$482.47M2.211.29 million shs1.63 million shsKYMRKymera Therapeutics$30.07-2.3%$29.57$19.45▼$53.27$1.96B2.18563,991 shs535,923 shsNAMSNewAmsterdam Pharma$18.37-4.7%$19.52$14.06▼$27.29$2.02B0.01620,020 shs974,266 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-3.38%-4.59%+27.95%+30.21%+2,430,999,900.00%ARVNArvinas-2.82%-14.38%-1.78%-64.65%-79.58%KYMRKymera Therapeutics-2.27%-14.77%+25.55%-19.43%-21.90%NAMSNewAmsterdam Pharma-4.67%-8.29%+15.83%-9.01%-15.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AARVNArvinas3.2323 of 5 stars4.32.00.00.01.72.51.3KYMRKymera Therapeutics1.9565 of 5 stars3.42.00.00.02.91.70.0NAMSNewAmsterdam Pharma3.0717 of 5 stars3.53.00.00.03.24.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AARVNArvinas 2.58Moderate Buy$20.91216.37% UpsideKYMRKymera Therapeutics 2.87Moderate Buy$56.3687.42% UpsideNAMSNewAmsterdam Pharma 3.00Buy$43.00134.08% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, NAMS, AAPG, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $40.005/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.005/5/2025ARVNArvinasTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$21.00 ➝ $11.005/2/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$16.005/2/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $19.005/2/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $8.005/2/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $16.005/2/2025ARVNArvinasPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$24.00 ➝ $14.005/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$81.00 ➝ $24.00(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M2.16N/AN/AN/A∞ARVNArvinas$426.90M1.13N/AN/A$8.17 per share0.81KYMRKymera Therapeutics$47.07M41.60N/AN/A$7.12 per share4.22NAMSNewAmsterdam Pharma$45.56M44.28N/AN/A$3.50 per share5.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group InternationalN/AN/A0.00∞N/AN/AN/AN/AN/AARVNArvinas-$198.90M-$0.66N/AN/AN/A-75.51%-33.75%-16.75%N/AKYMRKymera Therapeutics-$146.96M-$2.97N/AN/AN/A-191.26%-24.96%-20.27%5/9/2025 (Estimated)NAMSNewAmsterdam Pharma-$176.94M-$2.60N/AN/AN/AN/AN/AN/AN/ALatest ARVN, NAMS, AAPG, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million5/8/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A2/27/2025Q4 2024KYMRKymera Therapeutics-$0.76-$0.88-$0.12-$0.88$14.81 million$7.39 million2/26/2025Q4 2024NAMSNewAmsterdam Pharma-$0.48-$0.95-$0.47-$0.95$3.30 million$12.77 million2/11/2025Q4 2024ARVNArvinas-$1.07-$0.63+$0.44-$0.63$62.79 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group InternationalN/AN/AN/AARVNArvinasN/A4.644.64KYMRKymera TherapeuticsN/A8.558.55NAMSNewAmsterdam PharmaN/A10.6110.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AARVNArvinas95.19%KYMRKymera TherapeuticsN/ANAMSNewAmsterdam Pharma89.89%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AARVNArvinas5.23%KYMRKymera Therapeutics15.82%NAMSNewAmsterdam Pharma19.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.07 millionN/AN/AARVNArvinas42072.99 million65.18 millionOptionableKYMRKymera Therapeutics17065.12 million54.52 millionOptionableNAMSNewAmsterdam Pharma4109.82 million74.37 millionOptionableARVN, NAMS, AAPG, and KYMR HeadlinesRecent News About These CompaniesNewAmsterdam Pharma (NAMS) to Release Quarterly Earnings on WednesdayMay 9 at 7:10 AM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Alyeska Investment Group L.P.May 9 at 4:51 AM | marketbeat.comAxa S.A. Sells 66,387 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)May 9 at 4:41 AM | marketbeat.comDecoding NewAmsterdam Pharma Co NV (NAMS): A Strategic SWOT InsightMay 9 at 1:16 AM | gurufocus.comBuy Rating Affirmed for NewAmsterdam Pharma: Strategic Progress and Financial Stability Drive ConfidenceMay 8 at 2:18 PM | tipranks.comNewAmsterdam Pharma’s Promising Phase III Results and Strategic Plans Garner Buy RatingMay 8 at 1:19 PM | tipranks.comNewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue EstimatesMay 8 at 10:30 AM | zacks.comNewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsMay 8 at 8:00 AM | globenewswire.comCutter Capital Management LP Buys Shares of 337,152 NewAmsterdam Pharma (NASDAQ:NAMS)May 8 at 7:25 AM | marketbeat.comTudor Investment Corp ET AL Buys New Shares in NewAmsterdam Pharma (NASDAQ:NAMS)May 8 at 4:18 AM | marketbeat.comNewAmsterdam Pharma Presents Promising Phase 3 Trial DataMay 7 at 8:20 AM | tipranks.comNewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025May 7 at 7:15 AM | globenewswire.comBellevue Group AG Purchases 17,300 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)May 7 at 5:48 AM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Consensus Target Price from BrokeragesMay 5, 2025 | americanbankingnews.comAcuta Capital Partners LLC Makes New $1.29 Million Investment in NewAmsterdam Pharma (NASDAQ:NAMS)May 4, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) is RA Capital Management L.P.'s 7th Largest PositionMay 3, 2025 | marketbeat.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comMonashee Investment Management LLC Invests $1.29 Million in NewAmsterdam Pharma (NASDAQ:NAMS)May 2, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Rating of "Buy" from AnalystsMay 2, 2025 | marketbeat.comNewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS CongressApril 30, 2025 | gurufocus.comNewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS CongressApril 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, NAMS, AAPG, and KYMR Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$24.31 -0.85 (-3.38%) As of 05/9/2025 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Arvinas NASDAQ:ARVN$6.61 -0.20 (-2.94%) As of 05/9/2025 04:00 PM EasternArvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Kymera Therapeutics NASDAQ:KYMR$30.07 -0.70 (-2.27%) As of 05/9/2025 04:00 PM EasternKymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.NewAmsterdam Pharma NASDAQ:NAMS$18.37 -0.90 (-4.67%) As of 05/9/2025 04:00 PM EasternNewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Why Flutter Entertainment May Be a Resilient Sports Betting Stock OXY Stock Rebound Begins Following Solid Earnings Beat Is Energy Transfer Undervalued or a Value Trap? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
